Britannia Industries

Transcription

Britannia Industries
Company Update
INDIA
CONSUMER STAPLES
7 January 2015
BUY
Britannia Industries
TP: INR 2,200.00
 10.2%
BRIT IN
Outlook strong; raising earnings/TP – maintain BUY
We raise our FY16/FY17 earnings for BRIT by ~13%/14% on expectations of
continued benefits flowing in from mix improvements, cost synergies and a
muted RM inflation outlook. We built in a 350bps margin expansion over
FY14-FY17, leading to a strong EBITDA/PAT CAGR of 29% over this period.
An increase in A&P spends in H2FY15/FY16 should lead to market share
gains, while margins could surprise on lower RM costs. We roll over to a
Mar’16 TP of Rs 2,200 (from Rs 1,800 earlier) and maintain BUY on the stock.
REPORT AUTHORS
Gaurang Kakkad
+91 22 6766 3470
gaurang.kakkad@religare.com
 Topline growth at 14.6% CAGR: We expect BRIT to report a 14.6% revenue CAGR
over FY14-FY17 with volume growth likely to average at ~7-8%. We expect the
company to continue benefiting from the premiumisation of its portfolio, with
premium-end offerings likely to see a higher growth rate (20% YoY) than the lower
end segment. Despite a benign input cost scenario (flattish RM cost Index YoY), the
company is likely to take 2-3% price hikes each year as competitive intensity in the
sector has remained muted.
Premal Kamdar
 Margins to expand 350bps over FY14-FY17: We expect BRIT to report a 29%
EBITDA CAGR over FY14-FY17 as margins likely improve from ~8% in FY14 to ~11.5%
in FY17. A richer product mix coupled with a benign input cost scenario would shore
up gross margins by 300bps over FY14-FY17, while the company also benefits from
operating leverage due to cost rationalisation measures. BRIT is also likely to
increase A&P spends from 8.3% in FY15 to 8.9% in FY17 as it tries to gain back
market share from competitors. We expect a 29% PAT CAGR over FY14-FY17 on the
back of strong margins.
INR 1,995.75
 Upgrading earnings; TP revised to Rs 2,200: We raise our FY16/FY17 earnings for
BRIT by ~13%/14% on expectations of strong margins due to premiumisation
benefits, benign input costs and operating leverage. We roll over to a Mar’16 TP of
Rs 2,200 (from a Dec’15 TP of Rs 1,800). Maintain BUY.
3M AVG DAILY VOLUME/VALUE
+91 22 6766 3469
premal.kamdar@religare.com
PRICE CLOSE (07 Jan 15)
MARKET CAP
INR 239.3 bln
USD 3.8 bln
SHARES O/S
119.5 mln
FREE FLOAT
49.0%
0.1 mln / USD 3.8 mln
52 WK HIGH
52 WK LOW
INR 1,926.95
INR 809.10
Financial Highlights
Y/E 31 Mar
FY13A
FY14A
FY15E
FY16E
FY17E
Revenue (INR mln)
61,359
68,293
78,358
89,706
1,02,738
EBITDA (INR mln)
3,710
5,438
7,817
9,885
11,776
Adjusted net profit (INR mln)
2,595
3,956
5,581
7,058
8,413
Adjusted EPS (INR)
21.7
33.0
46.5
58.8
70.1
Adjusted EPS growth (%)
29.9
51.8
41.1
26.5
19.2
DPS (INR)
7.1
10.7
15.4
19.5
23.3
ROIC (%)
43.6
45.2
68.2
97.5
132.8
Adjusted ROAE (%)
53.7
58.4
59.0
55.0
49.7
Adjusted P/E (x)
91.9
60.5
42.9
33.9
28.5
EV/EBITDA (x)
64.6
44.3
30.6
23.9
19.7
P/BV (x)
42.7
30.0
21.9
16.3
12.5
(INR)
Stock Price
Index Price
29,400
1,790
1,290
24,400
790
19,400
290
14,400
Source: Company, Bloomberg, RCML Research
This report has been prepared by Religare Capital Markets Limited or one of its affiliates. For analyst certification and other important disclosures, please refer to the Disclosure and Disclaimer section at the end of
this report. Analysts employed by non-US affiliates are not registered with FINRA regulation and may not be subject to FINRA/NYSE restrictions on communications with covered companies, public appearances, and
trading securities held by a research analyst account.
BUY
Britannia Industries
TP: INR 2,200.00
 10.2%
BRIT IN
Company Update
INDIA
CONSUMER STAPLES
Per Share Data
Y/E 31 Mar (INR)
FY13A
FY14A
FY15E
FY16E
FY17E
Reported EPS
21.7
33.0
46.5
58.8
70.1
Adjusted EPS
21.7
33.0
46.5
58.8
70.1
7.1
10.7
15.4
19.5
23.3
46.7
66.5
91.3
122.6
159.9
FY13A
FY14A
FY15E
FY16E
FY17E
3.9
3.5
3.0
2.6
2.3
EV/EBITDA
64.6
44.3
30.6
23.9
19.7
Adjusted P/E
91.9
60.5
42.9
33.9
28.5
P/BV
42.7
30.0
21.9
16.3
12.5
FY13A
FY14A
FY15E
FY16E
FY17E
EBITDA margin
6.0
8.0
10.0
11.0
11.5
EBIT margin
4.9
6.7
8.7
9.8
10.3
Adjusted profit margin
4.2
5.8
7.1
7.9
8.2
Adjusted ROAE
53.7
58.4
59.0
55.0
49.7
ROCE
28.6
33.9
42.1
41.8
39.1
Revenue
12.4
11.3
14.7
14.5
14.5
EBITDA
29.6
46.6
43.8
26.4
19.1
Adjusted EPS
29.9
51.8
41.1
26.5
19.2
153.3
(0.3)
(5.1)
(14.9)
(8.0)
DPS
BVPS
Valuation Ratios
Y/E 31 Mar (x)
EV/Sales
Financial Ratios
Y/E 31 Mar
Profitability & Return Ratios (%)
YoY Growth (%)
Invested capital
Working Capital & Liquidity Ratios
Receivables (days)
Inventory (days)
7
6
6
6
6
38
35
35
35
35
Payables (days)
53
43
44
44
43
Current ratio (x)
0.9
0.8
1.0
1.2
1.4
Quick ratio (x)
0.1
0.1
0.3
0.5
0.7
Gross asset turnover
4.7
4.6
4.6
4.9
5.1
Total asset turnover
3.3
3.4
3.3
3.0
2.9
Net interest coverage ratio
7.2
55.6
136.3
195.4
318.2
Adjusted debt/equity
0.5
0.1
(0.2)
(0.5)
(0.6)
FY13A
FY14A
FY15E
FY16E
FY17E
72.4
69.5
69.0
69.0
69.0
120.3
123.6
118.7
116.3
115.4
Turnover & Leverage Ratios (x)
DuPont Analysis
Y/E 31 Mar (%)
Tax burden (Net income/PBT)
Interest burden (PBT/EBIT)
EBIT margin (EBIT/Revenue)
4.9
6.7
8.7
9.8
10.3
Asset turnover (Revenue/Avg TA)
330.9
339.8
327.2
304.1
285.1
Leverage (Avg TA/Avg equities)
383.6
296.5
253.0
229.9
212.7
53.7
58.4
59.0
55.0
49.7
Adjusted ROAE
7 January 2015
Page 2 of 4
BUY
Britannia Industries
TP: INR 2,200.00
 10.2%
BRIT IN
Company Update
INDIA
CONSUMER STAPLES
Income Statement
Y/E 31 Mar (INR mln)
FY13A
FY14A
FY15E
FY16E
FY17E
Total revenue
61,359
68,293
78,358
89,706
1,02,738
EBITDA
3,710
5,438
7,817
9,885
11,776
EBIT
2,979
4,606
6,816
8,793
10,568
Net interest income/(expenses)
(413)
(83)
(50)
(45)
(33)
Other income/(expenses)
1,017
1,170
1,322
1,481
1,658
Exceptional items
0
0
0
0
0
EBT
3,583
5,693
8,088
10,229
12,193
Income taxes
(986)
(1,736)
(2,507)
(3,171)
(3,780)
0
0
0
0
0
(2)
(2)
0
0
0
2,595
3,956
5,581
7,058
8,413
Extraordinary items
Min. int./Inc. from associates
Reported net profit
Adjustments
0
0
0
0
0
2,595
3,956
5,581
7,058
8,413
FY13A
FY14A
FY15E
FY16E
FY17E
6,749
7,982
9,061
10,132
11,448
0
0
0
0
0
Provisions
2,786
3,321
4,853
6,137
7,316
Debt funds
3,610
1,672
1,672
1,672
1,672
0
0
0
0
0
239
240
240
240
240
Reserves & surplus
5,339
7,741
10,710
14,465
18,941
Shareholders' fund
5,578
7,981
10,950
14,705
19,181
18,745
20,980
26,560
32,670
39,640
Cash and cash eq.
1,029
1,091
3,825
8,582
13,513
Accounts receivables
1,228
1,087
1,288
1,451
1,675
Inventories
3,747
4,203
4,789
5,356
6,051
Other current assets
2,905
3,163
3,643
4,135
4,729
Investments
1,082
1,979
1,979
1,979
1,979
Net fixed assets
7,368
8,543
9,527
9,660
10,185
CWIP
1,473
1,473
1,473
1,473
1,473
0
0
0
0
0
(86)
(86)
(86)
(86)
(86)
Adjusted net profit
Balance Sheet
Y/E 31 Mar (INR mln)
Accounts payables
Other current liabilities
Other liabilities
Equity capital
Total liabilities and equities
Intangible assets
Deferred tax assets, net
Other assets
0
0
0
0
0
Total assets
18,746
21,452
26,439
32,549
39,519
FY13A
FY14A
FY15E
FY16E
FY17E
3,327
4,788
6,582
8,149
9,622
413
83
50
45
33
0
0
0
0
0
(158)
1,194
1,343
1,135
981
Cash Flow Statement
Y/E 31 Mar (INR mln)
Net income + Depreciation
Interest expenses
Non-cash adjustments
Changes in working capital
Other operating cash flows
30
84
192
45
33
3,612
6,149
8,167
9,374
10,669
(2,154)
(2,007)
(1,985)
(1,225)
(1,733)
2,150
(897)
0
0
0
Other investing cash flows
286
0
0
0
0
Cash flow from investing
282
(2,904)
(1,985)
(1,225)
(1,733)
0
Cash flow from operations
Capital expenditures
Change in investments
Equities issued
0
(4)
0
0
Debt raised/repaid
(2,268)
(1,938)
0
0
0
Interest expenses
(413)
(83)
(50)
(45)
(33)
(3,937)
Dividends paid
(1,189)
(1,811)
(2,612)
(3,303)
Other financing cash flows
(423)
(83)
(50)
(45)
(33)
Cash flow from financing
(4,293)
(3,919)
(2,712)
(3,393)
(4,004)
Changes in cash and cash eq
(399)
(674)
3,470
4,756
4,932
Closing cash and cash eq
1,029
355
3,825
8,582
13,513
7 January 2015
Page 3 of 4
RESEARCH DISCLAIMER
Important Disclosures
This report was prepared, approved, published and distributed by a Religare Capital Markets
(“RCM”) group company located outside of the United States (a “non-US Group Company”). This
report is distributed in the U.S. by Enclave Capital LLC (“Enclave Capital”), a U.S. registered broker
dealer, on behalf of RCM only to major U.S. institutional investors (as defined in Rule 15a-6 under the
U.S. Securities Exchange Act of 1934 (the “Exchange Act”)) pursuant to the exemption in Rule 15a-6
and any transaction effected by a U.S. customer in the securities described in this report must be
effected through Enclave Capital. Neither the report nor any analyst who prepared or approved the
report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc.
(“FINRA”) or other regulatory requirements pertaining to research reports or research analysts. No
non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of
the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization.
Subject to any applicable laws and regulations at any given time, non-US Group Companies, their
affiliates or companies or individuals connected with RCM (together, “Connected Companies”) may
make investment decisions that are inconsistent with the recommendations or views expressed in this
report and may have long or short positions in, may from time to time purchase or sell (as principal or
agent) or have a material interest in any of the securities mentioned or related securities or may have
or have had a business or financial relationship with, or may provide or have provided investment
banking, capital markets and/or other services to, the entities referred to herein, their advisors and/or
any other connected parties. Any particular arrangements or relationships are disclosed below. As a
result, recipients of this report should be aware that Connected Companies may have a conflict of
interest that could affect the objectivity of this report.
See “Special Disclosures” for certain additional disclosure statements, if applicable.
This report is only for distribution to investment professionals and institutional investors.
Analyst Certification
Each of the analysts identified in this report certifies, with respect to the companies or securities that
the individual analyses, that (1) the views expressed in this report reflect his or her personal views
about all of the subject companies and securities and (2) no part of his or her compensation was, is
or will be directly or indirectly dependent on the specific recommendations or views expressed in this
report.
Analysts and strategists are paid in part by reference to the profitability of RCM.
Stock Ratings are defined as follows
Recommendation Interpretation (Recommendation structure changed with effect from March 1, 2009)
Recommendation
Buy
Hold
Sell
Expected absolute returns (%) over 12 months
More than 15%
Between 15% and –5%
Less than –5%
Expected absolute returns are based on the share price at market close unless otherwise stated.
Stock recommendations are based on absolute upside (downside) and have a 12-month horizon. Our
target price represents the fair value of the stock based upon the analyst’s discretion. We note that
future price fluctuations could lead to a temporary mismatch between upside/downside for a stock
and our recommendation.
Stock Ratings Distribution
As of 1 January 2015, out of 194 rated stocks in the RCM coverage universe, 109 have BUY ratings
(including 7 that have been investment banking clients in the last 12 months), 59 are rated HOLD and
26 are rated SELL.
Research Conflict Management Policy
RCM research has been published in accordance with our conflict management policy, which is
available here.
Disclaimers
This report is not directed to, or intended for distribution to or use by, any person or entity who is a
citizen or resident of or located in any locality, state, country or other jurisdiction where such
distribution, publication, availability or use would be contrary to law or regulation or which would
subject RCM to any registration or licensing requirement within such jurisdiction(s). This report is
strictly confidential and is being furnished to you solely for your information. All material presented in
this report, unless specifically indicated otherwise, is under copyright to RCM. None of the material,
its content, or any copy of such material or content, may be altered in any way, transmitted, copied or
reproduced (in whole or in part) or redistributed in any form to any other party, without the prior
express written permission of RCM. All trademarks, service marks and logos used in this report are
trademarks or service marks or registered trademarks or service marks of RCM or its affiliates, unless
specifically mentioned otherwise.
not treat recipients as its customers by virtue of their receiving the report. The investments or
services contained or referred to in this report may not be suitable for you and it is recommended that
you consult an independent investment advisor if you are in doubt about such investments or
investment services. In addition, nothing in this report constitutes investment, legal, accounting or tax
advice or a representation that any investment or strategy is suitable or appropriate to your individual
circumstances or otherwise constitutes a personal recommendation to you.
Information and opinions presented in this report were obtained or derived from sources that RCM
believes to be reliable, but RCM makes no representations or warranty, express or implied, as to their
accuracy or completeness or correctness. RCM accepts no liability for loss arising from the use of the
material presented in this report, except that this exclusion of liability does not apply to the extent that
liability arises under specific statutes or regulations applicable to RCM. This report is not to be relied
upon in substitution for the exercise of independent judgment. RCM may have issued, and may in the
future issue, a trading call regarding this security. Trading calls are short term trading opportunities
based on market events and catalysts, while stock ratings reflect investment recommendations based
on expected absolute return over a 12-month period as defined in the disclosure section. Because
trading calls and stock ratings reflect different assumptions and analytical methods, trading calls may
differ directionally from the stock rating.
Past performance should not be taken as an indication or guarantee of future performance, and no
representation or warranty, express or implied, is made regarding future performance. Information,
opinions and estimates contained in this report reflect a judgment of its original date of publication by
RCM and are subject to change without notice. The price, value of and income from any of the
securities or financial instruments mentioned in this report can fall as well as rise. The value of
securities and financial instruments is subject to exchange rate fluctuation that may have a positive or
adverse effect on the price or income of such securities or financial instruments. Investors in
securities such as ADR’s, the values of which are influenced by currency volatility, effectively assume
this risk.
This report is distributed in India by Religare Capital Markets Limited, which is a registered
intermediary regulated by the Securities and Exchange Board of India. In Dubai, it is being
distributed by Religare Capital Markets (Hong Kong) Limited (Dubai Branch) which is licensed and
regulated by the Dubai Financial Services Authority. In Singapore, it is being distributed (i) by
Religare Capital Markets (Singapore) Pte. Limited (“RCMS”) (Co. Reg. No. 200902065N) which is
a holder of a capital markets services licence and an exempt financial adviser in Singapore and (ii)
solely to persons who qualify as ““institutional investors” or “accredited investors” as defined in
section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore (the “SFA”). Pursuant to
regulations 33, 34, 35 and 36 of the Financial Advisers Regulations (the “FAR”), sections 25, 27 and
36 of the Financial Advisers Act, Chapter 110 of Singapore shall not apply to RCMS when providing
any financial advisory service to an accredited investor, or “overseas investor” (as defined in
regulation 36 of the FAR). Persons in Singapore should contact RCMS in respect of any matters
arising from, or in connection with this publication/communication. In Hong Kong, it is being
distributed by Religare Capital Markets (Hong Kong) Limited (“RCM HK”), which is licensed and
regulated by the Securities and Futures Commission, Hong Kong. In Australia, it is being distributed
by RCMHK which is approved under ASIC Class Orders. In Sri Lanka, it is being distributed by
Bartleet Mallory Stockbrokers, which is licensed under Securities and Exchange Commission of
Sri Lanka. If you wish to enter into a transaction please contact the RCM entity in your home
jurisdiction unless governing law provides otherwise. In jurisdictions where RCM is not registered or
licensed to trade in securities, transactions will only be effected in accordance with applicable
securities legislation which may vary from one jurisdiction to another and may require that the trade
be made in accordance with applicable exemptions from registration or licensing requirements.
Religare Capital Markets does and seeks to do business with companies covered in our research
report. As a result, investors should be aware that the firm may have a conflict of interest that could
affect the objectivity of research produced by Religare Capital Markets. Investors should consider
our research as only a single factor in making their investment decision.
Any reference to a third party research material or any other report contained in this report represents
the respective research organization's estimates and views and does not represent the views of RCM
and RCM, its officers, employees do not accept any liability or responsibility whatsoever with respect
to its accuracy or correctness and RCM has included such reports or made reference to such reports
in good faith. This report may provide the addresses of, or contain hyperlinks to websites. Except to
the extent to which the report refers to material on RCM’s own website, RCM takes no responsibility
whatsoever for the contents therein. Such addresses or hyperlinks (including addresses or
hyperlinks to RCM’s own website material) is provided solely for your convenience and information
and the content of the linked site does not in any way form part of this report. Accessing such
website or following such link through this report or RCM’s website shall be at your own risk.
Special Disclosures (if applicable)
Not Applicable
The information, tools and material presented in this report are provided to you for information
purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or
to buy or subscribe for securities or other financial instruments. RCM has not taken any steps to
ensure that the securities referred to in this report are suitable for any particular investor. RCM will
7 January 2015
Page 4 of 4